Breaking News, Collaborations & Alliances

ESSA Pharma, Janssen Partner for Trial of EPI-7386 Combinations in Prostate Cancer

ESSA will conduct a Phase 1 trial evaluating the safety, pharmacokinetics, drug-drug interactions, and Janssen will supply apalutamide and abiraterone acetate.

ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, entered into a clinical trial support agreement with Janssen Research & Development LLC, to enable evaluation of ESSA’s first-in-class N-terminal domain androgen receptor inhibitor, EPI-7386, in combination with apalutamide as well as the combination of EPI-7386 with abiraterone acetate plus prednisone in patients with prostate cancer. ESSA will spons...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters